Pirkko Kellokumpu‐Lehtinen
- Oncology top 1%
- Cancer Treatment and Pharmacology 24
- HER2/EGFR in Cancer Research 9
- Cancer survivorship and care 8
- Cancer Research top 2%
- Breast Cancer Treatment Studies 14
-
- Prostate Cancer Treatment and Research 11
- Immunology top 5%
- Reproductive Medicine top 5%
-
- Urological Disorders and Treatments 9
-
- Palliative Care and End-of-Life Issues 8
-
- Urologic and reproductive health conditions 8
Pirkko Kellokumpu‐Lehtinen
141 papers receiving 4.6k citations
Hit Papers
Peers
Comparison fields: 5 of 148
- Oncology 2.4k
- Cancer Research 995
- Pulmonary and Respiratory Medicine 993
- Immunology 617
- Reproductive Medicine 181
Countries citing papers authored by Pirkko Kellokumpu‐Lehtinen
This map shows the geographic impact of Pirkko Kellokumpu‐Lehtinen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pirkko Kellokumpu‐Lehtinen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pirkko Kellokumpu‐Lehtinen more than expected).
Fields of papers citing papers by Pirkko Kellokumpu‐Lehtinen
This network shows the impact of papers produced by Pirkko Kellokumpu‐Lehtinen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pirkko Kellokumpu‐Lehtinen. The network helps show where Pirkko Kellokumpu‐Lehtinen may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Pirkko Kellokumpu‐Lehtinen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 1 | |
| 2 | 2019 | 95 | |
| 3 | 2019 | 9 | |
| 4 | 2016 | 55 | |
| 5 | 2013 | 34 | |
| 6 | No additional benefit of adding ifosfamide to docetaxel in castration-resistant metastatic prostate cancer. | 2012 | 2 |
| 7 | 2011 | 20 | |
| 8 | Impact of radiotherapy and chemotherapy on biomarkers of oxidative DNA damage in lung cancer patients | 2009 | 2 |
| 9 | 2009 | 23 | |
| 10 | 2007 | 27 | |
| 11 | 2007 | 55 | |
| 12 | 2006 | 7 | |
| 13 | 2000 | 217 | |
| 14 | 1996 | 3 | |
| 15 | 1995 | 6 | |
| 16 | 1995 | 43 | |
| 17 | 1992 | 14 | |
| 18 | 1991 | 3 | |
| 19 | 1990 | 107 | |
| 20 | 1989 | 20 |
About Pirkko Kellokumpu‐Lehtinen
Pirkko Kellokumpu‐Lehtinen is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 143 papers that have together received 4.7k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (24 papers), Breast Cancer Treatment Studies (14 papers), Prostate Cancer Treatment and Research (11 papers), Urological Disorders and Treatments (9 papers), HER2/EGFR in Cancer Research (9 papers), Palliative Care and End-of-Life Issues (8 papers), Cancer survivorship and care (8 papers) and Urologic and reproductive health conditions (8 papers). The work is most often cited by research in Oncology (2.4k citations), Cancer Research (995 citations) and Pulmonary and Respiratory Medicine (993 citations). Pirkko Kellokumpu‐Lehtinen has collaborated with scholars based in Finland, Sweden and United States. Frequent co-authors include Ulla-Sisko Lehto, Petri Bono, Vesa Kataja, Heikki Joensuu, L. J. Pelliniemi, Mark J. Smyth, Carsten Denkert, Sibylle Loibl, Martine Piccart and Christine Desmedt. Their work appears in journals such as Journal of Clinical Oncology, Acta Oncologica, Annals of Oncology, Journal of Cancer Research and Clinical Oncology and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.